CME POST-TEST AND EVALUATION FORM

CME Record of Completion

Complex Cardiometabolic Risk Factors: Impact,Assessment, and Emerging Therapies

There is No Fee for this activity.

Release Date: August 31, 2006. Expires on August 31, 2007

Name: ___________________________________________Degree: _________________

Address: ____________________________________________________________________________________________

City: ___________________________ State: ____________Zip: _____________________

Phone: _______________________________Email: _______________________________

Post-test

Circle the letter of the appropriate answer:

1. In the United States, what percentage of the adult pop-ulation is now considered overweight (BMI �25 kg/m2)?

a. 80%b. 66%

c. 50%d. 25%

2. Between 2000 and 2001, the results of a random phonesurvey in the United Sates indicated that the preva-lence of obesity and type II diabetes increased by aboutwhat percentage?

a. 1 to 2%b. 3 to 4%

c. 5 to 10%d. 20 to 25%

3. NCEP ATP III criteria for metabolic syndrome includewhich of the following factors?

a. Abdominal Obesity (waist circumference) of�102 cm (�40 in) in men, and �88 cm(�35 in) in women

b. HDL �40 mg/dL in men and �50 mg/dL inwomen

c. Fasting glucose �110 mg/dLd. All of the above

4. Based on NHANES III data, which included 8814adults in the United States, what percentage of adultshave metabolic syndrome?

a. 10%b. 15%

c. 22%d. 39%

SYMPOSIUM REPORTER

5. NHANES III data indicate that which of the followingfactors is the most common feature in individuals withmetabolic syndrome?

a. Abdominal obesityb. Hypertensionc. Hyperglycemiad. Hypertriglyceridemia

6. In elderly individuals, the metabolic syndrome hasbeen linked to accelerated cognitive decline, especiallyin the presence of

a. Dyslipidemiab. Poor nutrition

c. Inflammationd. Insulin resistance

7. Which exercise regimen has been shown to be most ben-eficial in elevating HDL-cholesterol in individuals over50 years of age with a history of cardiovascular disease?

a. High-intensity, home-basedb. Low-intensity, home-basedc. High-intensity, group-basedd. Low-intensity, group-based

8. In nondiabetic individuals at high-risk for type II dia-betes, which primary prevention approach was mostsuccessful in delaying diabetes onset after 4 years?

a. Lifestyle modification: moderate-intensity exer-cise and low-calorie, low-fat diet

b. Metformin therapyc. Moderate exercise aloned. Calorie-restricted diet alone

9. Which of the following agents are currently availablein the United States for the long-term management ofobesity?

a. Orlistat, sibutramine, and phentermineb. Orlistat and phenterminec. Sibutramine and phentermined. Orlistat and sibutramine

10. Which of the following are the principal endogenousendocannabinoids?

a. 2-AG and anandamideb. THC and 2-AGc. FAAH and 2-AGd. FAAH and anandamide

11. In rodents, activation of CB1 receptors in the hypo-thalamus results in:

a. Decreased eating behaviorb. Increased eating behaviorc. Sudden weight lossd. No changes in eating behavior or weight

12. CB1 receptors are localized in the central nervous system.a. Trueb. False

11

13. In obese women, levels of the endogenous endocan-nabinoid anandamide have been shown to be elevatedby what percentage, when compared with lean women?

a. 10%b. 25%

c. 35%d. 55%

14. In the RIO-North America trial, rimonabant 20 mgdaily maintained weight and waist circumference re-ductions for up to:

a. 6 monthsb. 1 year

c. 2 yearsd. 3 years

15. After one year, data from the Rio-North America,RIO-Lipid, and Rio-Europe trials revealed that rimon-abant 20 mg daily yields improvements in which com-ponents of the metabolic syndrome?

a. Triglyceride levelb. HDL-cholesterolc. Waist circumferenced. All of the above

16. In the RIO-Diabetes trial, what percentage of thediabetic subjects experienced at least a 5% weight losswith rimonabant 20 mg daily treatment?

a. About 10%b. Almost 50%

c. About 66%d. Over 90%

17. In subjects with diabetes, rimonabant 20 mg therapy

12

yielded significant improvements, compared with pla-cebo, in which of the following metabolic factors?

a. HbA1cb. Triglyceridesc. HDL-cholesterold. All of the above

18. Pooled data from all four RIO clinical trials revealedthat about what percentage of the effect of rimonabanton cardiometabolic risk factors is independent ofweight loss?

a. 25%b. 50%

c. 66%d. 75%

19. Which of the following is a weight-independent actionof rimonabant?

a. Increase in HDL-Cholesterolb. Decrease in triglyceridesc. Decrease in fasting insulind. All of the above

20. Clinical trial with rimonabant suggest that the mostcommon side effects include:

a. Diarrhea, flatulence, and abdominal painb. Increased blood pressure and pulsec. Gastrointestinal symptoms, depressed mood, and

anxiety

d. All of the above

General evaluation

Please rate the following: (1 � Poor; 5 � Excellent)

Met learning objectives 1 2 3 4 5I learned something new that was important to my

practice.1 2 3 4 5

I plan to seek more information on this topic 1 2 3 4 5Was this educational activity free from commercial bias? Yes No

By signing below, I verify that I have completed the following home-study program, “Complex Cardiometabolic Risk Factors:Impact, Assessment, and Emerging Therapies”Signature: ___________________________________ Date: ________________________

This activity has been planned and implemented in accordance with Essential Areas and Policies of the Accreditation Councilfor Continuing Medical Education through the joint sponsorship of the University of Cincinnati, College of Medicine and TheGMR Group-Health Insights.

The University of Cincinnati, College of Medicine is accredited by the Accreditation Council for Continuing Medical Educationto provide continuing medical education for physicians.The University of Cincinnati, College of Medicine designates this education activity for a maximum of 1.5 Category 1 creditstoward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent onthe educational activity.Time actually spent on this activity: ______________________ minutesTo receive continuing education credit, mail or fax all pages of this form to:

Office of Continuing Medical EducationU.C. College of MedicineP.O. Box 670556Cincinnati, OH 45267-0556FAX: (513) 558-1756

JAMDA – September 2006